CV Sciences' physicians and scientists contributed to the growing body of scientific evidence on hemp-derived CBD as a non-prescription product.
CV Sciences, Inc. (OTCQB:CVSI), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pleased to announce the publication of two papers in the Journal of Dietary Supplements' first Special Issue on Cannabinoids.
In this issue, CV Sciences' team of physicians and scientists took the opportunity to contribute to the growing body of scientific evidence on hemp-derived CBD as a non-prescription product.
Dr. Douglas Mackay, N.D., Senior Vice President of Scientific and Regulatory Affairs for CV Sciences teamed up with Cannabis expert and academic Dr. Igor Koturbash, M.D., Ph.D., Associate Professor and Vice-Chair of Environmental and Occupational Health at the Fay W. Boozman College of Public Health, the University of Arkansas for Medical Sciences as co-editors of the Special Issue on Cannabinoids and provided the editorial, "Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway." The editorial outlines the intent of the Special Issue on Cannabinoids, which is to address key scientific questions related to benefits, safety, and composition of popular hemp-derived CBD products.
Now, I am proud to say that CV Sciences is the only CBD company that has published toxicology studies, randomized, placebo-controlled clinical trials, and a systematic evaluation of post-market safety data of our products.Duffy MacKay, ND, Senior Vice President of Clinical and Regulatory Affairs for CV Sciences
Dr. Osvaldo Marinotti, Ph.D., Senior Scientist, CV Sciences, and Miles Sarill, M.Sc., National Educator for CV Sciences, co-authored, "Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science."
Both papers intended to add peer-reviewed scientific evidence that supports FDA's request for "data that may help to address uncertainties and data gaps related to CBD, including real world evidence to address safety questions".
Joseph Dowling, CV Sciences Chief Executive Officer, stated, "Observations from the food, supplement and cosmetic industries suggest that consumers expect a responsible, transparent, and science backed industry, that is fully FDA regulated. We agree with consumers, and that's why we continue to lead the industry in advancing CBD science and regulatory compliance. We are proud to contribute our team's expertise to this important cannabinoid report in the Journal of Dietary Supplements. These efforts help develop a framework for an FDA regulated industry that consumers can trust."
The same Special Issue on Cannabinoids in the Journal of Dietary supplements also published the two previously announced research studies demonstrating the safety and health benefits of PlusCBD™ products:
Published on May 25, 2020, "Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience," this study adds to the growing body of literature that supports the safe use of hemp-derived CBD as a dietary supplement. The data confirm a low rate of adverse effects in millions of consumers taking PlusCBD™ products over a two-year period. A noteworthy finding was the absence of any reports of liver toxicity, which has been described in studies using high doses of CBD as a prescription drug.
Lead author Stephen Schmitz, MD, MPH and co-founder of Supplement Safety Solutions, stated, "This is the first longitudinal study of a CBD dietary supplement being used in real-world conditions. This study represents two years of data and daily product use from millions of consumers and demonstrates that CV Sciences' products are safe and well tolerated."
Published on May 27, 2020, "Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects," this study used PlusCBD™ products to determine their benefits on stress resilience, perceived recovery, mood, affect, body composition, and clinical safety markers in healthy human subjects.
Lead author Hector L. Lopez, M.D., CSCS, FAAPMR, FISSN, commented, "In a first of its kind study, participants taking PlusCBD™ products had significant improvement in HDL cholesterol compared to placebo, while improvements in measures of stress response, life pleasure, wellness and sleep were also observed. We also found an excellent safety profile, with no adverse signals in liver or other biomarkers of health in the group treated with PlusCBD™ products."
Duffy MacKay, ND, Senior Vice President of Clinical and Regulatory Affairs for CV Sciences, stated, "These studies add to the growing evidence supporting the safety and benefits of hemp-derived CBD by tracking participant experience and health outcomes while taking CV Sciences' proprietary CBD products. In 2018, CV Sciences achieved self-affirmed GRAS (Generally Recognized as Safe) status as a result of our extensive non-clinical testing program."
The peer-reviewed manuscripts created an opportunity for scientific and policy debate from a variety of expert viewpoints, including the article by P.S. Cogan, Ph.D., "Reality and Legality: Disentangling What is Actual from What is Tolerated in Comparison of Hemp Extracts with Pure CBD," which suggested that hemp products with CBD are more appropriately regulated in alignment with current tobacco regulations. CV Sciences advocates that hemp-derived CBD products are dietary supplements, and we recognize that transparent public debate regarding these important issues are a critical component for sensible hemp-derived product regulations to be enacted.
To learn more about CV Sciences, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors